# US 2016/0354025 A1 · Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354025 A1
- Document ID: US20160354025A1
- Status: Published application
- Kind: A1
- Application number: 15/238,149
- Filed: 2016-08-16
- Published: 2016-12-08
- Earliest claimed: 2013-09-30
- Assignees: Horizon Therapeutics, LLC
- Applicants: Horizon Therapeutics, LLC
- Inventors: Bruce Scharschmidt; Masoud Mokhtarani; Marzena Jurek
- Web page: https://patentgrep.com/patent/US20160354025A1

## CPC

- A61B 5/165: {Evaluating the state of mind, e.g. depression, anxiety}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods, systems, and instruments for the determination by a physician or medical professional whether a subject is experiencing or has recently experienced an overt HE episode and for grading overt HE episodes as well as methods, systems, instruments and tools for screening for overt HE episodes by a non-medical professional such as a caregiver. Also provided are methods of treating HE episodes and methods of monitoring HE episode treatment that incorporate these methods, systems, instruments, and tools.

## Claims

### Claim 1

A method of determining whether a subject is experiencing an overt HE episode comprising:
(a) determining whether the subject has been disoriented as to time, place, or person for at least one hour;
(b) determining whether the subject has been lethargic for at least one hour and is exhibiting asterixis; and/or
(c) determining that the subject is incapable of being assessed due to disorientation as to time, place, and person, somnolence, or coma,
wherein the subject is classified as experiencing an overt HE episode if they meet any one of the criteria set forth in (a), (b), or (c).

### Claim 2 (depends on 1)

The method of claim 1, wherein a therapeutic intervention is administered to the subject if the subject meets any one of the criteria set forth in (a), (b), or (c).

### Claim 3 (depends on 2)

The method of claim 2, wherein the therapeutic intervention is administered at a dosage sufficient to maintain the subject's fasting blood ammonia level at or below a specified threshold of 1.5 times the upper limit of normal.

### Claim 4 (depends on 2)

The method of claim 2, wherein the therapeutic intervention is a nitrogen scavenging drug.

### Claim 5 (depends on 4)

The method of claim 4, wherein the nitrogen scavenging drug is selected from the group consisting of a PAA prodrug and sodium benzoate.

### Claim 6

A method of treating an HE episode in a subject in need thereof, comprising:
(a) determining whether a subject is experiencing at least a grade 2 HE episode by
(i) determining whether the subject has been disoriented as to time, place, or person for at least one hour and/or
(ii) determining whether the subject has been lethargic for at least one hour and is exhibiting asterixis,
wherein the subject is classified as experiencing at least a grade 2 HE episode if they meet the criteria set forth in either (i) or (ii);
(b) determining whether a subject is experiencing at least a grade 3 HE episode by
(iii) determining whether the subject has been disoriented as to time, place, and person for at least one hour and/or
(iv) determining whether the subject has been somnolent for at least one hour, wherein the subject is classified as experiencing at least a grade 3 HE episode if they meet the criteria set forth in either (iii) or (iv); and
(c) determining whether a subject is experiencing at least a grade 3 HE episode by
(v) determining whether the subject is comatose, wherein the subject is classified as experiencing a grade 4 HE episode if they meet the criteria set forth in (v); and
(d) administering a therapeutic intervention if the subject is classified as experiencing a grade 2, 3, or 4 HE episode under steps (a), (b), or (c).

### Claim 7 (depends on 6)

The method of claim 6, wherein the therapeutic intervention is administered at a dosage sufficient to maintain the subject's fasting blood ammonia level at or below a specified threshold of 1.5 times the upper limit of normal.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutic intervention is a nitrogen scavenging drug.

### Claim 9 (depends on 8)

The method of claim 8, wherein the nitrogen scavenging drug is selected from the group consisting of a PAA prodrug and sodium benzoate.

### Claim 10 (depends on 9)

The method of claim 9, wherein the PAA prodrug is selected from the group consisting of glyceryl tri-[4-phenylbutyrate] (HPN-100), phenylbutyric acid (PBA), sodium PBA (NaPBA), and a combination of two or more of HPN-100, PBA, and NaPBA.

### Claim 11

A tool for screening a subject in need thereof for HE symptoms comprising:
(a) a first set of steps comprising one or more steps selected from:
(i) determining whether the subject has unusual difficulty speaking,
(ii) determining whether the subject is exhibiting unusual behavior, and
(iii) determining whether the subject is more forgetful or confused than usual; and
(b) a second set of steps comprising one or more steps selected from:
(iv) determining whether the subject can stay awake when being spoken to,
(v) determining whether the subject is disoriented as to person,
vi) determining whether the subject is disoriented as to place, and
(vii) determining whether the subject is disoriented as to time,
wherein the second set of steps is performed only if one or more criteria from the first set of steps are met, and
wherein a user is instructed to contact a physician if one or more criteria from the second set of steps are met.

### Claim 12 (depends on 11)

The tool of claim 11, wherein the user is a caregiver of the subject in need thereof

### Claim 13 (depends on 12)

The tool of claim 12, wherein the first and, if necessary, second set of steps are performed on a daily basis to monitor the subject.

### Claim 14 (depends on 13)

The tool of claim 13, wherein the steps of the tool are provided in a questionnaire format.

### Claim 15 (depends on 14)

The tool of claim 14, wherein the tool is provided in an electronic format with a branching logic algorithm.

### Claim 16 (depends on 15)

The tool of claim 15, wherein the tool is provided on a web-enabled device.

### Claim 17 (depends on 16)

The tool of claim 16, wherein daily reminders are electronically sent to the caregiver at the same time each day to remind the caregiver to use the tool.

### Claim 18 (depends on 12)

The tool of claim 12, wherein the subject in need thereof is administered a therapeutic intervention according to the physician's recommendation if one or more criteria are met from the second set of steps.

### Claim 19 (depends on 18)

The tool of claim 18, wherein if the subject was previously administered a dosage of lactulose, the dosage of lactulose is increased and the increased dosage of lactulose is administered to the subject.

### Claim 20 (depends on 18)

The tool of claim 18, wherein the therapeutic intervention is administered at a dosage sufficient to maintain the subject's fasting blood ammonia level at or below a specified threshold of 1.5 times the upper limit of normal.
